The Current and Future Roles of Immunotherapies in the Multimodal Treatment of Esophageal Cancer

6,825
Total downloads
19k
Total views and downloads

Articles

CASE REPORT

Published on 21 Jun 2024

Thrombocytopenia and hyperprogression after radiotherapy and camrelizumab treatment in an esophageal cancer patient with increased JAK2 gene copies: a case report

Hang Wang
Yun Li
Min Qiu
Jianmin Wang

doi 10.3389/fonc.2024.1283428

594 views
1 citation

ORIGINAL RESEARCH

Published on 08 May 2024

Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma

Guozhen Yang
Haodong Yue
Xiaomin Zhang
Chufeng Zeng
Linyu Tan
Xu Zhang

doi 10.3389/fimmu.2024.1336798

1,039 views

ORIGINAL RESEARCH

Published on 25 Apr 2024

To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment

Zhou Yehan
Qin Sheng
Yang Hong
Li Jiayu
Hou Jun
Ji Juan
Shi Min
Yan Jiaxin
Hu Shangzhi
6 more
Huang Zongyao

doi 10.3389/fimmu.2024.1312380

1,269 views

REVIEW

Published on 19 Feb 2024

Perioperative immunotherapy for esophageal squamous cell carcinoma

Dan D. Wei
Jin M. Fang
Huan Z. Wang
Jian Chen
Shuai Kong
Yan-Yi Jiang
Yuan Jiang

doi 10.3389/fimmu.2024.1330785

1,914 views
1 citation

STUDY PROTOCOL

Published on 11 Jan 2024

Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study

Hesong Wang
Xueyuan Zhang
Xiaohan Zhao
Chunyang Song
Wenzhao Deng
Wenbin Shen

doi 10.3389/fimmu.2023.1330928

1,281 views
3 citations

MINI REVIEW

Published on 13 Dec 2023

Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma

Clemence J. Belle
James M. Lonie
Sandra Brosda
Andrew P. Barbour

doi 10.3389/fimmu.2023.1330635

1,788 views
1 citation

BRIEF RESEARCH REPORT

Published on 25 Oct 2023

A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma

Jifeng Feng
Liang Wang
Xun Yang
Qixun Chen
Xiangdong Cheng

doi 10.3389/fimmu.2023.1217967

1,183 views
1 citation

ORIGINAL RESEARCH

Published on 12 Oct 2023

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

James M. Lonie
Sandra Brosda
Vanessa F. Bonazzi
Lauren G. Aoude
Kalpana Patel
Ian Brown
Sowmya Sharma
Guy Lampe
Venkateswar Addala
4 more
Andrew P. Barbour

doi 10.3389/fimmu.2023.1220129

1,657 views
4 citations

REVIEW

Published on 04 Oct 2023

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial

Yan Lin
Huan-Wei Liang
Yang Liu
Xin-Bin Pan

doi 10.3389/fimmu.2023.1264912

7,452 views
2 citations

Share on

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.5 impact factor
- 6.2 citescore

Impact

19kTopic views
11kArticle views
6,825Article downloads

View impact

Submit your idea

Articles

Thrombocytopenia and hyperprogression after radiotherapy and camrelizumab treatment in an esophageal cancer patient with increased JAK2 gene copies: a case report

Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma

To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment

Perioperative immunotherapy for esophageal squamous cell carcinoma

Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study

Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma

A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial

Frontiers in Immunology

Participating Journals

Impact